Charles Schwab Investment Management Inc. Raises Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Charles Schwab Investment Management Inc. raised its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 2.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 423,947 shares of the company’s stock after purchasing an additional 8,417 shares during the period. Charles Schwab Investment Management Inc. owned 0.44% of ARS Pharmaceuticals worth $6,147,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in shares of ARS Pharmaceuticals during the third quarter worth about $30,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of ARS Pharmaceuticals by 151.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock worth $63,000 after buying an additional 4,472 shares during the last quarter. Principal Financial Group Inc. purchased a new position in shares of ARS Pharmaceuticals in the second quarter worth $87,000. TFG Advisers LLC purchased a new stake in shares of ARS Pharmaceuticals during the third quarter valued at $180,000. Finally, J.W. Cole Advisors Inc. grew its holdings in shares of ARS Pharmaceuticals by 10.8% during the second quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock valued at $131,000 after buying an additional 1,500 shares during the last quarter. 68.16% of the stock is currently owned by institutional investors.

ARS Pharmaceuticals Stock Down 5.3 %

Shares of SPRY opened at $12.27 on Thursday. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -24.06 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a 52 week low of $5.01 and a 52 week high of $18.51. The stock’s 50-day moving average price is $14.69 and its 200-day moving average price is $12.32.

Analyst Ratings Changes

Several research firms have weighed in on SPRY. William Blair upgraded ARS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Finally, Leerink Partners increased their price target on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a report on Friday, September 20th. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, ARS Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $24.00.

Insider Transactions at ARS Pharmaceuticals

In other news, insider Eric Karas sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the completion of the sale, the insider now directly owns 5,693 shares in the company, valued at $79,702. The trade was a 63.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Sarina Tanimoto sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $13.16, for a total value of $1,316,000.00. Following the transaction, the insider now directly owns 1,148,499 shares of the company’s stock, valued at approximately $15,114,246.84. The trade was a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,215,786 shares of company stock valued at $18,999,286 in the last 90 days. 40.10% of the stock is currently owned by company insiders.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.